Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the United States are in short supply and have played little role in the fight against the omicron wave of infections.
Eli Lilly inks R&D pact with Canadian pharma company
Indianapolis-based Eli Lilly and Co. will make an initial $50 million payment to Entos Pharmaceuticals. Entos also could receive up to $400 million in potential milestone payments, as well as royalties, for successful products.Read More
Feds buy another $1.29B worth of Lilly antibody treatment for COVID-19
The purchase will amount to 614,000 doses of two drugs, bamlanivimab and etesevimab, that make up the drug-cocktail infusion, Lilly said.Read More
Lilly misses earnings estimates but raises full-year outlook
Indianapolis-based Eli Lilly and Co. saw revenue in the third quarter increase 18 percent over the same period of 2020, to $6.77 billion.Read More
Vaccine booster mix-and-match approach poised for FDA clearance
Preliminary results of a U.S. government-sponsored trial found that mixing coronavirus vaccines produces as much or more antibodies as using the same shot as a booster.Read More
Medicare officials stressed Tuesday that they did not take cost into account in the coverage decision, but rather whether Aduhelm is “reasonable and necessary” for treating Alzheimer’s patients enrolled in the program.
U.S. health secretary Xavier Becerra on Monday ordered Medicare to reassess a big premium increase facing millions of seniors this year, attributed in large part to a pricey new Alzheimer’s drug with questionable benefits.
The federal government has resumed shipping all three monoclonal antibody treatments—including one made by Indianapolis-based Eli Lilly and Co.—that are authorized for early-stage COVID-19 to states despite evidence that two might be ineffective against the omicron variant.
Germany-based pharmaceutical giant Merck on Thursday announced it has signed a definitive agreement to buy Indianapolis-based drug contract manufacturer Exelead Inc.
Easy-to-take antiviral pills, authorized just before Christmas, were hailed as a potential turning point in the fight against the coronavirus because of the medicines’ ability to keep high-risk people out of the hospital.
Boosters already are recommended for everyone 16 and older, and federal regulators on Monday decided they’re also warranted for 12- to 15-year-olds once enough time has passed since their last dose.
Eli Lilly’s blockbuster drug for osteoporosis, Forteo, could face generic competition from Indian drugmaker Sun Pharmaceuticals if the company can get a federal judge to declare that a Lilly patent won’t be infringed.
Molnupiravir cut the risk of hospitalization and death in high-risk patients by 30%. In contrast, Pfizer’s antiviral drug, authorized on Wednesday, reduced hospitalizations and death by nearly 90%.
The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections and head off the worst effects of the virus. But initial supplies will be extremely limited.
Orano Med LLC says the facility will be used to manufacture and distribute radiopharmaceuticals to treat cancer at hospitals throughout the country.
The companies say they can quickly develop new omicron-targeting antibodies, but those aren’t expected to launch for at least several months.
The chairman of the company’s board, Steve Miller, said in a statement that the ruling would “delay and perhaps end the ability of creditors, communities, and individuals to receive billions in value to abate the opioid crisis.”
The strange clotting problem has caused nine confirmed deaths after J&J vaccinations—while the Pfizer and Moderna vaccines don’t come with that risk and also appear more effective, said advisers to the Centers for Disease Control and Prevention.
On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech—if it’s been six months since their last shot.
People who could benefit from the antibody drug include cancer patients, organ transplant recipients and people taking immune-suppressing drugs for conditions like rheumatoid arthritis.
The biggest policy change—a system for Medicare to negotiate prices for prescription drugs—won’t begin to deliver lower costs until 2025, and then only for a selected set of 10 medicines, as well as insulin products.
CEO Ugur Sahin told Reuters on Friday that he could foresee a scenario where coronavirus vaccine shots became annual, like flu shots.
The Food and Drug Administration panel voted 13-10 that the antiviral drug’s benefits outweigh its risks, including potential birth defects if used during pregnancy.